Investigators generated hESCs lacking retinoblastoma tumor suppressor (RB) family proteins by introducing frameshift mutations in RBL1 and RBL2 genes using the CRISPR/Cas9 technology, and then integrating the shRNA-expression cassette to knockdown RB upon tetracycline treatment.
[PLoS One]
